Stockscreener 앱 받기
35.19
7.45%
2.44
시간 외 거래:
35.50
0.31
+0.88%
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
What makes LENZ Therapeutics Inc. stock price move sharplyFree Top-Rated Stock Analysis - Newser
Why LENZ Therapeutics Inc. stock attracts strong analyst attentionReliable High Profit Alerts - Newser
Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect? - Yahoo Finance
Versant funds sell $6.5 million in Lenz Therapeutics (LENZ) - Investing.com Australia
Versant funds sell $6.5 million in Lenz Therapeutics (LENZ) By Investing.com - Investing.com South Africa
Leerink Partnrs Has Bearish Outlook for LENZ FY2028 Earnings - Defense World
LENZ Therapeutics Shares Soar 4.93% on Strategic Partnership, Regulatory Milestone - AInvest
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada - VisionMonday.com
LENZ and Théa partner on Canadian commercialization of presbyopia eye drop - Eyes On Eyecare
LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada - Ophthalmology Times
Lenz Therapeutics stock gains as William Blair reiterates Outperform By Investing.com - Investing.com Nigeria
Lenz Therapeutics stock gains as William Blair reiterates Outperform - Investing.com
LENZ and Théa ink $70 million licensing deal for presbyopia treatment - Investing.com India
LENZ Therapeutics and Laboratoires Théa Announce Exclusive - GlobeNewswire
$70M Licensing Deal: LENZ Eyes Canadian Market with Breakthrough Presbyopia Treatment - Stock Titan
LENZ Therapeutics: A Pivotal Moment for Presbyopia and Potentially Transformative Returns - AInvest
LENZ Therapeutics: Presbyopia Eyedrops Look Promising (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) dropped from Russell Microcap Value Index - MarketScreener
LENZ Therapeutics: Ready To Test Its Potential (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics reports results of stockholder vote By Investing.com - Investing.com Nigeria
LENZ Therapeutics reports results of stockholder vote - Investing.com
LENZ Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Citi maintains Buy rating, $45 target on LENZ Therapeutics stock By Investing.com - Investing.com South Africa
Citi maintains Buy rating, $45 target on LENZ Therapeutics stock - Investing.com
Two Sigma Investments LP Has $493,000 Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Transcript : LENZ Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener
Bank of America Corp DE Boosts Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZLENZ Therapeutics Reports Third Quarter 2024 Financial Results - mx.advfn.com
Jane Street Group LLC Cuts Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
BNP Paribas Financial Markets Sells 859 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Lenz Therapeutics’ Earnings Call Highlights Strong Outlook - MSN
Deutsche Bank AG Purchases 4,370 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Holdings Boosted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Holdings Decreased by Ameriprise Financial Inc. - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of “Buy” by Analysts - Defense World
LENZ Therapeutics Prepares for LNZ100 Launch - TipRanks
7,447 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by D. E. Shaw & Co. Inc. - Defense World
LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decision - Investing.com Canada
LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics Showcases Revolutionary Eye Drop Treatment at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Northern Trust Corp Raises Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss - insights.citeline.com
Transcript : LENZ Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Tower Research Capital LLC TRC Has $54,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Taiwan's Lotus Pharma inks $125 M deal with LENZ Therapeutics to commercialise presbyopia treatment - BioSpectrum Asia
LENZ Therapeutics and Lotus partner for LNZ100 distribution in Asia - World Pharmaceutical Frontiers
LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment - Yahoo Finance
Raymond James Financial Inc. Takes $245,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Leerink Partnrs Analysts Raise Earnings Estimates for LENZ - Defense World
HC Wainwright Issues Negative Estimate for LENZ Earnings - Defense World
3.40%
2.49%
자본화:
|
볼륨(24시간):